CONCLUSION
This study proved the efficiency of pharmaceutical interviews in hypertension, type 2 diabetes and hypercholesterolemia, by doubling the proportion of patients reaching the therapeutic objectives after three months of a drug therapy. It also made possible to define preferential populations to benefit from these interventions, such as polypharmacy and type 2 diabetic patients.
However, further studies with larger samples are needed to conclude on an effect of the rest of the criteria such as multiple pathologies. Besides, some studies reported a temporary and short-term effect of this type of intervention[12,63]. We have deliberately limited this study to a single intervention and its evaluation after 3 months. Thus, further studies should focus on this effect on the long term, as well as the need for repeated pharmaceutical interventions several times a year, in person or by telephone[54]. In the same way, multicentric studies, will have to be conducted to refine our results. Moreover, we stayed focused on the clinical outcomes of these interventions, and we did not studied the benefits in terms of medicoeconomy and public health outcomes. Thus, further studies assessing the pharmaceutical costs of these interviews as well as the impact in terms of hospitalization, are necessary to evaluate the cost-benefit balance and the public health impact and have a comprehensive view of all the consequences of implementing such practices in routine.
This study confirms the interest of clinical pharmacy and of the evolution of pharmacists’ activities, such as medication reconciliation[66] and optimized medication reviews, experimented in community pharmacies since March 2018.